Skip to main content
MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. logo

MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. — Investor Relations & Filings

Ticker · 688062 ISIN · CNE100005RD2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 541 across all filing types
Latest filing 2026-01-28 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688062

About MABWELL (SHANGHAI) BIOSCIENCE CO., LTD.

https://www.mabwell.com/en/

Mabwell (Shanghai) Bioscience Co., Ltd. is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of therapeutic antibodies and innovative biologics. The company maintains an integrated R&D and manufacturing platform covering the full drug lifecycle, from target discovery and preclinical research to clinical development and commercial production. Its therapeutic pipeline addresses critical needs in oncology, autoimmune diseases, metabolic disorders, ophthalmology, and infectious diseases. Mabwell leverages proprietary technology platforms, including antibody-drug conjugates (ADCs), bispecific antibodies, and high-throughput screening, to develop a diverse portfolio of novel drug candidates and biosimilars. The organization is committed to delivering high-quality, accessible therapeutic solutions through its end-to-end biotechnological capabilities.

Recent filings

Filing Released Lang Actions
国泰海通证券股份有限公司关于迈威（上海）生物科技股份有限公司调整部分募投项目内部投资结构的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from Guotai Huatong Securities Co., Ltd. regarding the adjustment of internal investment structure of certain fundraising projects by Maiwei (Shanghai) Biotechnology Co., Ltd. It includes extensive financial data about the fundraising amounts, usage, and adjustments in investment allocations among various projects. The document references regulatory approvals, fundraising rules, and includes detailed tables of investment amounts before and after adjustments. It is not a full annual or interim report but a specific audit or verification opinion related to fundraising and investment structure adjustments. The document length is substantial (9936 characters), and it contains detailed financial and project data, not just an announcement or certification. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles related to fundraising and investment projects, excluding full annual reports. Therefore, the appropriate classification is AR with high confidence.
2026-01-28 Chinese
迈威生物关于公司调整部分募投项目内部投资结构的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from a company about adjustments to the internal investment structure of certain fundraising projects related to their antibody drug development. It includes extensive financial data on fundraising amounts, project investment changes, and risk disclosures. The document references the company's initial public offering fundraising and the allocation of those funds among various projects, with specific adjustments to amounts allocated to sub-projects. It also mentions board approval and the need for shareholder meeting approval. The content is focused on changes to the use of previously raised capital rather than new financing or capital raising. It is not a full annual or interim financial report, nor an earnings release or audit report. It is a formal announcement about changes in the use of raised funds, which fits the category of Capital/Financing Update (CAP). The document length and detail confirm it is not a brief announcement or a report publication notice. Therefore, the classification is CAP with high confidence.
2026-01-28 Chinese
迈威生物2025年年度业绩预告
Earnings Release Classification · 95% confidence The document is a 2025 annual performance forecast (业绩预告) for the company 迈威生物. It provides preliminary estimated net profit figures for the full year 2025, including expected losses, and compares them to the prior year. It explicitly states that the forecast has not been audited and that final audited financial data will be disclosed in the formal 2025 annual report. The document is relatively short (985 characters) and serves as a performance outlook announcement rather than a full financial report. This type of document is typically classified as an Earnings Release (ER) because it announces key financial results or forecasts for a fiscal period but does not contain full financial statements or detailed analysis like an Annual Report (10-K) or Interim Report (IR).
2026-01-23 Chinese
迈威生物关于预计2026年度日常关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company regarding its expected daily related-party transactions for the year 2026. It includes details about the nature of the transactions, the approval process by the board and audit committee, the expected transaction amounts, related parties, and the pricing policies. The document is a formal disclosure about ongoing and anticipated related-party transactions, which is typical for regulatory compliance and investor information. It does not contain financial statements, audit opinions, or detailed financial results. It is not a report like an Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). It is also not a meeting presentation, voting results, or management change announcement. The document is a regulatory announcement about related-party transactions, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2026-01-21 Chinese
国泰海通证券股份有限公司关于迈威（上海）生物科技股份有限公司继续使用部分暂时闲置募集资金进行现金管理的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from the sponsor (Guotai Huatong Securities Co., Ltd.) regarding the continued use of temporarily idle raised funds by Maiwei (Shanghai) Biotechnology Co., Ltd. for cash management. It references regulatory rules related to the management of raised funds, investment amounts, risk control measures, and the sponsor's audit and approval. The document is not a financial report like an annual or interim report, nor is it a simple announcement or certification. It is a formal audit or verification opinion related to the use of raised funds, which fits the category of an Audit Report / Information (AR). The document length is about 5,000 characters, and it contains substantive content rather than just an announcement or certification. Therefore, the best classification is AR (Audit Report / Information).
2026-01-21 Chinese
迈威生物关于继续使用部分暂时闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from a company regarding the continued use of temporarily idle raised funds for cash management. It details the investment types, amounts, board approval, risk analysis, and compliance with regulatory rules. The document is relatively short (3647 characters) and focuses on the announcement of a financing/capital management activity rather than presenting full financial statements or detailed financial results. It does not contain comprehensive financial data or results but rather informs about the company's decision and procedures related to cash management of raised funds. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2026-01-21 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.